Draft:Cytiva Inc.
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Life Sciences |
| Founded | 2020 |
Key people | Chris Riley, President and CEO |
Number of employees | 16,000 |
| Parent | Danaher Corporation |
| Website | cytivalifesciences.com |
Cytiva is an American life sciences company that provides technologies and services for the development and manufacture of therapeutics. It is headquartered in Marlborough, Massachusetts, and operates in over 40 countries with approximately 16,000 employees. Cytiva is a subsidiary of Danaher Corporation.
History Cytiva was established on March 31, 2020, after the acquisition of GE Healthcare Life Sciences by Danaher Corporation.[1] GE Healthcare Life Sciences originated in 2004 following General Electric's acquisition of Amersham Biosciences. Amersham's history includes the acquisition of the Swedish company Pharmacia, known for innovations in chromatography and protein purification.
In January 2023, Cytiva merged with the Life Science business unit of Pall Corporation, also part of Danaher since 2015.[2] This merger expanded Cytiva’s capabilities in bioprocessing and single-use technologies.
Products and Services Cytiva supports the biopharmaceutical industry across various stages of drug development and manufacturing. Key product areas include:
- Bioprocessing Solutions
* Chromatography Systems: Purification systems for biomolecules. * Filtration Systems: Depth filters and membrane filters. * Cell Culture Products: Media, supplements, and reagents. * Single-Use Technologies: Bioreactors, mixers, and connectors.
- Lab Filtration
* Whatman Filters: Laboratory filters, including filter papers and membranes.
- Protein Analysis
* Electrophoresis Equipment: Tools for protein separation. * Western Blotting Systems: Instruments for protein detection.
- Genomics and Cellular Research
* Nucleic Acid Purification Kits: Tools for DNA and RNA extraction. * PCR and qPCR Reagents: Reagents for nucleic acid amplification.
- Digital Solutions
* Cytiva Data Bridge: A digital tool that integrates data into quality management systems, enhancing compliance and reducing errors.
Market Presence Cytiva operates globally, offering its technologies to biopharma companies, research institutions, and contract manufacturers. The company’s portfolio includes industry-leading brands such as ÄKTA, Amersham, Biacore, and Whatman, with a focus on advancing bioprocessing technologies.
Mergers and Acquisitions Cytiva's growth has been driven by strategic acquisitions:
- Acquisition by Danaher: In 2020, Danaher acquired GE Healthcare Life Sciences, rebranding it as Cytiva.[3]
- Integration of Pall Biotech: In 2023, Cytiva merged with Pall Corporation's life sciences unit, enhancing capabilities in single-use systems and filtration.[4]
Research and Development Cytiva operates research and development centers in the United States, Sweden, and other locations, focusing on innovations in bioprocessing and therapeutic production.
Community and Sustainability Cytiva is committed to sustainability, aiming to reduce its environmental impact through sustainable manufacturing practices. The company also supports STEM education and community engagement programs in various regions.
Locations Cytiva’s key locations include:
- Headquarters: Marlborough, Massachusetts, USA.
- Manufacturing Sites: Facilities in the USA, Sweden, and China.
- German Locations: Cytiva Germany GmbH in Dreieich, Cytiva Europe GmbH in Freiburg and Munich, GoSilico in Karlsruhe, Global Life Sciences Solutions Germany GmbH in Dassel, and Cevec Pharmaceuticals GmbH in Cologne.
External Links
References
- ^ "Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva", PR Newswire, March 31, 2020.
- ^ "Cytiva and Pall Life Sciences Complete Integration", BioPharma Reporter, May 2, 2023.
- ^ "Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva", PR Newswire, March 31, 2020.
- ^ "Cytiva and Pall Life Sciences Complete Integration", BioPharma Reporter, May 2, 2023.